In a phase 1 trial, a PYY analogue (Y14 peptide) administered subcutaneously at 7- to 14-days intervals was safe and potentially efficacious (WL between 2.9 and 3.6 kg at 31 days, with a 3855% reduction in food intake vs
GLP-1 medications are designed to act on pathways involved in: Slower digestion and fullness cues Insulin response after meals Appetite signaling Blood sugar regulation Common GLP-1 medications include: Semaglutide Liraglutide Dulaglutide Tirzepatide A licensed provider may consider GLP-1 therapy for eligible patients with goals related to: Weight loss Prediabetes Type 2 diabetes Appetite control Metabolic support Your response depends on genetics, starting health, dosage, lifestyle habits, and how long GLP-1 stays active in your system
President Trump upon taking office reversed the Biden administrations plan to expand Medicare coverage by including GLP-1s for weight loss
The next phase of peptide curious and peptide driven discussions is going to be like how do you incorporate it into a giant health system
It is sold by research suppliers under research-use-only terms and is not intended for human consumption
Some are interested in the metabolic health benefits beyond weight loss, and GLP-1s are also being marketed as a longevity drug for their anti-inflammatory, cardiovascular, and cognitive benefits, among others
